|
|
|
|
| LEADER |
01177nam a2200241 u 4500 |
| 001 |
EB002220181 |
| 003 |
EBX01000000000000001357142 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
240703 r ||| eng |
| 245 |
0 |
0 |
|a CADTH Canadian Drug Expert Review Committee final recommendation: Riociguat (Adempas - Bayer HealthCare Inc.)
|h Elektronische Ressource
|b indication: pulmonary arterial hypertension
|
| 246 |
3 |
1 |
|a Riociguat (Adempas - Bayer HealthCare Inc.)
|
| 260 |
|
|
|a Ottawa (ON)
|b Canadian Agency for Drugs and Technologies in Health
|c 2015, 2015
|
| 300 |
|
|
|a 1 PDF file (6 pages)
|
| 710 |
2 |
|
|a CADTH Canadian Drug Expert Committee
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH common drug review
|
| 500 |
|
|
|a "Notice of Final Recommendation - December 17, 2015."
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK538738
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a The CADTH Canadian Drug Expert Review Committee (CDEC) recommends that riociguat be listed for the treatment of pulmonary arterial hypertension
|